BIIB · Full Picture

BIOGEN INC. — the full picture

Trailing window · 2026-05-12 to 2026-08-10

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 59
    2 forward row(s); quote_verified
    Biogen Inc. has completed the acquisition of RayThera, Inc. for a total consideration of $1 billion.
  2. Product / Drug Pipeline Progress · Products & launchesPriority 34
    quote_verified
    The lead program entered Phase 1 development in July 2026.
  3. Litigation and Legal Risk · Litigation & settlementsPriority 32
    1 forward row(s); quote_verified
    Biogen has reached a preliminary settlement agreement with investors who filed a class-action lawsuit alleging the company misrepresented clinical trial data for its Alzheimer's drug, Aduhelm; the terms of the settlement, including the financial amount, are not yet public but are expected to be filed within 60 days.
  4. Revenue Performance and Mix · Revenue growth & mixPriority 21
    quote_verified
    Biogen Inc. saw a significant drop in net income and diluted EPS in Q2 2026.

Threads by pillar

Revenue & Demand Priority 36 · 2 threads

Strategy & Portfolio Priority 59 · 1 thread

Legal, Regulatory & Policy Priority 32 · 1 thread